NCT04867642

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

A First-In-Human, Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled, Single- and Multiple-Dose, Dose-Escalating Study Evaluating the Safety, Tolerability, and Pharmacokinetics of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of UCB0022 and food effect.

Conditions

• Healthy Study Participants
• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	UCB0022	Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B, C and D.
OTHER	Placebo	Study participants will receive placebo comparator in a pre-specified sequence during the Treatment Period of Part A, B and C.

Timeline

• Start date: 2021-04-29
• Primary completion: 2023-02-27
• Completion: 2023-02-27
• First posted: 2021-04-30
• Last updated: 2025-11-18

Locations

1 site across 1 country: United Kingdom